New Hikma CEO Eyes M&A, Upbeat Despite Generic Advair Woes
Executive Summary
Sigurdur Olafsson is impressed with the balance sheet he has inherited at Hikma and said he is looking forward to both organic and inorganic growth.
You may also be interested in...
Stock Scan March 2018: Trading Down, Pairing Up
Merger and acquisition, or collaboration at least, was in the air during March as big pharma took stock of its opportunities in the midst of a disturbed market.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.